{"id":600,"date":"2016-01-21T16:06:38","date_gmt":"2016-01-21T16:06:38","guid":{"rendered":"https:\/\/www.vdh.virginia.gov\/epidemiology\/?page_id=600"},"modified":"2025-11-10T14:00:08","modified_gmt":"2025-11-10T14:00:08","slug":"hepatitis-chiv-co-infected-treatment-assistance-program","status":"publish","type":"page","link":"https:\/\/www.vdh.virginia.gov\/disease-prevention\/vamap\/hepatitis-chiv-co-infected-treatment-assistance-program\/","title":{"rendered":"Hepatitis C\/HIV Co-Infected Treatment Assistance Program"},"content":{"rendered":"
<\/div><\/div>
\n\t\t\t\n\t\t\n\t\t\t\n\t\t\tVirginia Medication Assistance Program (VA MAP)\t\t<\/span>\n\t\t\t<\/a>\n\t<\/div>\n<\/div><\/div><\/div>
\n\t\t\t\n\t\t\n\t\t\t\n\t\t\tCare Coordination Services\t\t<\/span>\n\t\t\t<\/a>\n\t<\/div>\n<\/div><\/div><\/div>
\n\t\t\t\n\t\t\n\t\t\t\n\t\t\tHIV Care Services\t\t<\/span>\n\t\t\t<\/a>\n\t<\/div>\n<\/div><\/div><\/div><\/div>
\n
\n\t

Hepatitis C is an inflammation of the liver caused by infection with the hepatitis C virus (HCV).\u00a0 HCV is a major cause of liver disease in the US and progresses more rapidly to liver damage in HIV-infected persons.\u00a0 The virus lives in the blood and is spread by contact with this infected blood through shared needles, sexual contact, or from an infected mother to a baby during delivery.<\/p>\n

It is estimated that 30% of persons with HIV in the United States (US) are co-infected with HCV.\u00a0 Risk factors of dual infection include accelerated hepatitis C disease progression, increased risk for liver disease, liver failure, and liver related death, and increased risk of transmission for hepatitis C.\u00a0 There is no vaccine for hepatitis C but persons infected with hepatitis C should be vaccinated to prevent hepatitis A and hepatitis B.\u00a0 Hepatitis C treatments can cure HCV.\u00a0 HCV treatments are improving by causing fewer side effects and having shorter treatment lengths.<\/p>\n

Clients that are enrolled in one of the insurance programs through VA MAP have access to HCV medications if they are available on their insurance plans formulary.\u00a0 VA MAP will pay for the medication co-pay\/cost share.\u00a0 If HCV medications are not available on the insurance plan formulary or the medication request is denied, clients can access Harvoni, Sovaldi, Daklinza, Zepatier, Epclusa, Mavyret and Viekira Pak through the treatment assistance program. \u00a0VA MAP will continue to be the payer of last resort and will continue to provide Ryan White services not covered by public or private health insurance plans.<\/p>\n

The Virginia Department of Health (VDH) provides a treatment assistance program for HCV\/HIV co-infected Virginia Medication Assistance Program (VA MAP) clients.\u00a0 The program provides Harvoni, Sovaldi,\u00a0 Zepatier, Epclusa, Mavyret, and if needed, ribavirin, and payments for associated medical care and labs for uninsured clients or those whose insurance does not cover those medications.<\/p>\n

The application process is initiated by the client\u2019s medical provider.\u00a0 All questions on the application must be completed, required documents much be attached, and the form must be signed by the client\u2019s medical provider applying for this assistance.\u00a0 Applications are reviewed by a clinical review team to ensure client is accessing the correct medication.<\/p>\n

Medications are shipped to the medical provider\u2019s site.\u00a0 In order for these medications to be shipped to the medical provider\u2019s site, a Controlled Substance Registration (CSR) must be established.\u00a0 Please contact Stephanie Wheawill, Director of Pharmacy Services, at 804-786-7326, to obtain the necessary documents.\u00a0 Medications may also be shipped to the client\u2019s Local Health Department of choice.\u00a0 Services provided through VA MAP\u2019s HCV\/HIV Treatment Assistance Program are dependent upon available funding.<\/p>\n

Eligibility criteria:<\/strong><\/p>\n